Fig. 3: Association of baseline molecular features with Ki67 at Day14. | Nature Communications

Fig. 3: Association of baseline molecular features with Ki67 at Day14.

From: Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies

Fig. 3

A Differences in Ki67 dynamics during treatment in the Fulv and NoFulv cohorts, two-sided Student’s t-test. B Evaluation of differences in Ki67 positivity in tumours from patients achieving or not pCR (overall cohort), two-sided Student’s t-test. C Selected genesets with a significant enrichment in the Day14 Ki67 high group (i.e. Ki67 > 10%) compared to low (i.e. Ki67 ≤ 10%), * = gene permutation FDR < 0.1%). D Association of PAM50 subtypes defined at baseline with Day14 Ki67, two-sided Fisher’s test. E Association between presence of PIK3CA mutation and Day14 Ki67, two-sided Fisher’s test. F Association between presence of TP53 mutation and Day14 Ki67, two-sided Fisher’s test. G Association of baseline sTILs with Day14 Ki67 in the overall population and per treatment cohort, two-sided Student’s t-test. H Association of baseline iTILs with Day14 Ki67 in the overall population and per treatment cohort, two-sided Student’s t-test. All boxplots are defined as follow: centre line = median; box limits = upper and lower quartiles; whiskers = 1.5x interquartile range; points = outliers. sTILs = stromal tumour infiltrating lymphocytes; iTILs = intra-tumoral infiltrating lymphocytes; pCR = pathologic complete response; RD = residual disease; NES = Normalised Enrichment score. Source data are provided as a Source Data file.

Back to article page